Cited 0 times in
Cited 0 times in
Phase III study of canakinumab (CAN) as adjuvant therapy in patients (pts) with completely resected non-small cell lung cancer (NSCLC)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.